Journal
AMERICAN JOURNAL OF TRANSPLANTATION
Volume 11, Issue 1, Pages 34-44Publisher
WILEY
DOI: 10.1111/j.1600-6143.2010.03335.x
Keywords
Acute allograft rejection; stem cells; tolerance induction; transplantation
Categories
Funding
- American Heart Association [09 BGIA 2190055]
- National Institutes of Health [K08 HL077503]
- NIH DERC [P30-DK057516]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL077503] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK057516] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Autologous CD117+ progenitor cells (PC) have been successfully utilized in myocardial infarction and ischemic injury, potentially through the replacement/repair of damaged vascular endothelium. To date, such cells have not been used to enhance solid organ transplant outcome. In this study, we determined whether autologous bone marrow-derived CD117+PC could benefit cardiac allograft survival, possibly by replacing donor vascular cells. Autologous, positively selected CD117+PC were administered posttransplantation and allografts were assessed for acute rejection. Although significant generation of recipient vascular cell chimerism was not observed, transferred PC disseminated both to the allograft and to peripheral lymphoid tissues and facilitated a significant, dose-dependent prolongation of allograft survival. While CD117+PC dramatically inhibited alloreactive T cell proliferation in vitro, this property did not differ from nonprotective CD117- bone marrow populations. In vivo, CD117+ PC did not significantly inhibit T cell alloreactivity or increase peripheral regulatory T cell numbers. Thus, rather than inhibiting adaptive immunity to the allograft, CD117+ PC may play a cytoprotective role in prolonging graft survival. Importantly, autologous CD117+PC appear to be distinct from bone marrow-derived mesenchymal stem cells (MSC) previously used to prolong allograft survival. As such, autologous CD117+PC represent a novel cellular therapy for promoting allograft survival.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available